FDA Seeks To End Industry’s Use Of Error-Prone Medical Abbreviations
This article was originally published in The Pink Sheet Daily
Executive Summary
In partnership with PhRMA, FDA and the Institute for Safe Medication Practices have launched a campaign to prevent error-prone notation from appearing in labels and advertisements.